Abstract: Steroid sulfatase (STS) in breast carcinoma is an important enzyme in intratumoral estrogen synthesis. Twenty-two paraffin-embedded surgical specimens from non-invasive ductal carcinoma (DCIS) of the breast and 32 specimens from invasive ductal carcinoma (IDC) were stained using the STS and estrogen receptor (ER) polychronal antibodies. Immunoreactivity for STS in ER positive tumor was 82 % (14/17) in DCIS, 75 % (12/16) in T1 and 56% (5/9) in T2 without lymph node involvement. The incidence of immunoreactivity for STS of DCIS tended to be higher than that of IDC, although it did not reach statistical difference. These results suggest that STS in breast carcinoma may be involved in the process of carcinogenesis of the breast.
Introduction
The efficacy of aromatase inhibitor as a hormone therapy for breast carcinoma')2) has gained increasing interest in intratumoral estrogen synthesis. Estrogen in breast carcinoma is produced through two main pathways, one from aromatase, which converts androgen to estrogen3) and the other from steroid sulfatase (STS), which converts biological inactivate estrogen sulfate to activate free estrogen4). The established main therapies for hormonedependent breast cancer involve either antagonizing estrogen receptor activity with selective estrogen receptor modulators (e.g., tamoxifen) or reducing levels of estrogens using aromatase inhibitors. The ATAC trials) was designed to compare the efficacy and safety of aromatase inhibitor (e.g., anastrozole) versus tamoxifen for the adjuvant treatment of postmenopausal women with operable, invasive early breast carcinoma. After a median follow-up of 47 months, anastrozole demonstrated superior efficacy compared with tamoxifen in terms of disease-free survival, time to recurrence, and reduction in the incidence of contralateral breast carcinoma. Twenty-two paraffin-embedded surgical specimens from DCIS of the breast between July 2000 and April 2003 were immunohistochemical stained for STS and estrogen receptor (ER). It was compared with that of 32 specimens from IDC of the breast without lymph node involvement, where 20 were T1 (n0 T1) and 12 were T2 (n0 T2). In n0 T2 group, 12 IDC consisted of 6 with papillotubular carcinoma, 4 with scirrhous carcinoma and 2 with solid tubular carcinoma. In this study, the paraffin-embedded surgical specimens from the central region of the tumor were used for the immunohistochemistry.
STS staining was performed according to our previous report8. Briefly, formalin-fixed, paraffin-embedded tissue was cut into 3-tim sections. The immunohistochemical localization of STS was investigated using the streptavidin-biotin method. Endogenous peroxidase activity was blocked using 3 % H2O2 for 20 min at room temperature. After dehydrating and washing with PBS, the immunostaining was performed using polyclonal rabbit antihuman STS antibody g) diluted in 1: 1000. The STS antibody was donated by Dr. Y. Osawa affiliation. The antigen for preparation of this antibody was purified from human placenta using immunoaffinity chromatography. Specificity of the antibody was confirmed by staining a normal human term placenta and STS-deficient placenta diagnosed from Southern blot analysis of STS gene lo). MCF-7 breast carcinoma cell line, which was obtained from American Type Culture Collection (Rockville, MD), was used for positive control. STS and ER mRNA of MCF-7 were detected by reverse transcription polymerase chain reaction (RT PCR) . STS staining was evaluated by our scoring criteria. In our previous report, the scoring criteria of the 0, no staining ; 1, weak diffuse cytoplasmic staining (may contain stronger intensity in less than 25% of the cancer cells) ; 2, moderate to strong granular cytoplasmic staining in 25%50% -of cancer cells ; 3, over 50% of the tumor cells stained with strong intensity. Immunoreactivity of STS was evaluated in 54 invasive breast carcinomas, of which 9.3% (5154) were score 0 and 19% (10154) score 1, 20% (11154) score 2, and 52% (28154) score 3. Five-year distant disease free survival (DDFS) in patients with STS score 0 or 1, and score 2 or 3 tumor was 86.7% and 79.5%, respectively 11) . Because STS score 2 or 3 tumor group showed poorer DDFS than STS score 0 or 1 tumor group, the positive expression of STS was defined as score 2 or 3, which was positive for cytoplasmic immunoreactivity of 25% or more of cancer cells Immunostaining for ER was carried out using the ER antibody (Ventana, Strasbourg, France), and it was evaluated to be positive when 10% or more cancer cells expressed ER stain 12). Statistical analysis was performed using the Fisher's exact test.
Results

STS expression
was observed in the cytoplasm of carcinoma cells present in DCIS and IDC of the breast using immunohistochemistry (Fig. 1) . Clinical and immunohistochemical features of 22 cases in DCIS of the breast are presented in Table 1 . The patients were between 30 and 79 years old (median age, 47.5 years).
Tumor size was between three and 40 mm (median size, 6 mm). Immunostaining for STS showed positive staining in 18 of 22 (82%), and negative staining in four of 22 (18%). Two of three patients over 70 years old showed negative for STS staining. The remaining two cases with negative STS staining carcinoma were 37 and 46 years old patients. Immunostaining for ER was positive in 19 of 22 cases (86%), and negative in three of 22 (14%). Two of three carcinomas with negative ER staining had positive staining for STS staining, and one carcinoma from a 72-year-old woman was negative for both STS and ER staining. Positivity of STS staining was 82% (18 / 22) in DCIS, 75% (15 l 20) in n0 T1 and 67% (8112) in n0 T2, respectively. It was not significantly different between DCIS and n0 T1 or n0 T2 (P = 0.71, P = 0.41, respectively). For ER staining, the positive rate was 77% (17 / 22) in DCIS, 80% (16120) in n0 T1 and 75% (9112) in n0 T2, respectively. Immunoreactivity for STS in ER positive tumor was 82% (14117) in DCIS, 75% (12116) in n0 T1 and 56% (519) in n0 T2, respectively. There was also no significant difference between DCIS and n0 Ti or n0 T2 (P = 0.69, P = 0.19, respectively). In our cases, tumors negative for ER staining were three. Two of the three tumors were from 48-year-old patients, and they were positive for STS staining. One of the three tumors was from a 72-year-old patient, and it was negative for STS staining. walking et a114) reported the relationship between ER and the metabolism of estrone sulfate in breast carcinoma from patients with low peripheral estrogen levels. The transformation of [3H] estrone sulfate into [3H] estradiol-1713 was significantly higher in the ER poor group than in the ER rich group, and the mean age of the ER poor group was significantly younger than that of the ER rich group. It may be suggested that the difference in tumor estrogen metabolism could reflect an age-dependent decrease in the tumor STS.
STS is responsible for hydrolysis of estrone sulfate to estrone and estradiol sulfate to estradiol, and this pathway is important in breast carcinoma, as it results in up to ten times more free E1 than the aromatase pathway 6). In our cases, the positivity of STS staining in DCIS was higher than that in T1 and T2. This leakage became stronger in ER positive carcinoma. Results of the ATAC trial showed that anastrozole significantly reduced the development of contralateral breast carcinoma after 5 year's adjuvant treatment for hormone receptor-positive tumor 1 . Therefore, the estrogen-converting enzymes such as aromatase and STS may play a particular important role in the carcinogenesis of the breast. Recently, STS has been a recognized oncology target, and its role in hormone-dependent breast carcinoma has currently been investigated in a phase I clinical trial's . It has been reasoned that inhibitors of STS given in conjunction with aromatse inhibitors should maximize estrogen depletion in treated patients. While administering an STS inhibitor in conjunction with an aromatase inhibitor is an obvious approach, an alternative approach is to design a dual aromatase-steroid sulfatase inhibitor (DASI) that will inhibit both enzymes as a single agent. Lloyd et al 15) reported the crystal structures of a new DASI drug, and a method for its stable and relatively efficient delivery. According to the development of the new DASI drug, an endocrine therapy of estrogen-converting enzyme against DCIS of breast may be expected for the future.
